Finance entity
All 3 tracked stories fall under one category: markets. CRISPR Therapeutics is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 2.7 for the same window.
Last mentioned: Sep 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: markets. CRISPR Therapeutics is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 2.7 for the same window. The 177-day window averages about 0.1 stories each week. The 5.3 average consequence score is below the beat benchmark of 6.2 in the same window. We currently track 3 Finance stories that mention Vertex Pharmaceuticals, published between March 11, 2026 and September 3, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 3047 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vertex Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Offering Upsized
The company prices an upsized $550M offering due to strong institutional interest.
ARK Invest Trade
Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
Debt Offering Announced
CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.
CRISPR Therapeutics has lagged the broader market in 2026, but Casgevy's label expansion and upcoming clinical readouts create two discrete catalysts that could re-rate the stock. Downside risk remains from slow uptake and high cost.
Vertex's $10B cash acquisition of Crinetics sets a powerful precedent, suggesting Viking Therapeutics could command a $15–20B price tag in a consolidating obesity market. For investors, VKTX's late-stage pipeline and the appetite of cash-rich pharma giants offer a high-risk, high-reward M&A setup.
ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
Vertex Pharmaceuticals is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
